Psychoendocrine investigation in schizophrenia: relationship between pituitary-gonadal function and behavior.
The Authors examine possible connections between the schizophrenic syndrome and the hypothalamo-pituitary-gonadal system, assuming that hormonal impairments may correlate with the appearance and development of peculiar behavioral features. The hormonal status and the behavioral parameters have been examined before, during and after a psychopharmacological therapy, and a combination of a psychopharmacological-hormonal treatment. Data have been obtained in 12 male hebephrenic schizophrenics, aged 18-36 years, with onset of the disease between 12 months and 20 years before our experiments. The patients were treated for 30 days with Haloperidol (6 mg.i.m.p.d. to a total dose of 180 mg.) and then for 45 days with Haloperidol at the same dose in combination with Chorionic Gonadotrophin (5000 I.U.i.m. twice a week for a total dose of 60.000 I.U.). The following hormonal assays were performed: total urinary gonadotrophins, serum FSH and LH, total urinary 17 ketosteroids, total urinary estrogens, serum testosterone. The hormonal assays were performed twice prior to therapy, twice during the Haloperidol therapy (12th and 26th days) twice during the Haloperidol plus HCG therapy (20th and 40th day) and 1 month after the withdrawal of the therapy. The psychological-behavioral parameters were examined through the Wittenborn Rating Scale. The result obtained seem to reveal a stimulatory effect of the Haloperidol plus HCG therapy on the deficient hormonal status. Moreover, it is evident that a constant correlation exists between biochemical improvement and behavioral improvement, especially in regard to affectivity disorders, adjustment to reality, active behavior.
Brambilla
F
F
Ospedale Paolo Pini, Milano Affori, Italy.
Guerrini
A
A
Riggi
F
F
Ricciardi
F
F
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001519:Behavior; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006728:Hormones / Q000097:blood; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D008297:Male; D010902:Pituitary Gland / Q000503:physiopathology*; D011569:Psychiatric Status Rating Scales; D012562:Schizophrenia, Disorganized / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D012565:Schizophrenic Psychology; D013737:Testis / Q000503:physiopathology*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D006063:Chorionic Gonadotropin; D006728:Hormones; D006220:Haloperidol